ANALYSIS OF PHARMACOLOGICAL THERAPY OF A NEW CORONAVIRUS INFECTION IN KSMU STUDENTS

  • Authors: Dubinina M.1, Boldina N.V.2
  • Affiliations:
    1. Kursk state medical university
    2. Курский государственный медицинский университет
  • Issue: Vol 11, No 1 (2022): XVI МЕЖДУНАРОДНАЯ НАУЧНО-ПРАКТИЧЕСКАЯ КОНФЕРЕНЦИЯ МОЛОДЫХ УЧЕНЫХ-МЕДИКОВ
  • Pages: 73-75
  • Section: Современные вызовы медицинского сообщества. COVID-19 - прикладные и клинические исследования
  • URL: https://new.vestnik-surgery.com/index.php/2415-7805/article/view/7593

Cite item

Abstract

With the appearance of the Omicron strain, the prevalence of coronavirus infection among a younger group of the adult population has increased significantly [1-3], which means that statistical data on the incidence of a new coronavirus infection, their absolute and relative growth determine the relevance of improving approaches to CoViD-2019 therapy within the framework of current temporary clinical recommendations. According to the results of the study of this sample, it can be said that special attention deserves the fact that most cases of transmission of a new coronavirus infection in the studied population are not confirmed by PCR testing for the detection of SARS-CoV-2 RNA, which may affect the incidence statistics, as well as the treatment protocol in each individual clinical case. The highest frequency of use in the treatment of NKVI was observed in such drugs as umifenovir (27.9%), gripferon in the form of nasal drops (27.9%), vitamin C (60.5%), vitamin D (44.2%), and vitamin B (20.9%). The therapy of a new coronavirus infection used by students corresponds to the schemes described in the temporary clinical recommendations for the treatment of NCVI [2], and is also effective.

Full Text

With the appearance of the Omicron strain, the prevalence of coronavirus infection among a younger group of the adult population has increased significantly [1-3], which means that statistical data on the incidence of a new coronavirus infection, their absolute and relative growth determine the relevance of improving approaches to CoViD-2019 therapy within the framework of current temporary clinical recommendations.
The purpose of the study is to conduct a study among KSMU students on the subject of their transfer of a new coronavirus infection to study the features of the pharmacological therapy of the disease used by them.
To conduct a sociological survey, a questionnaire was developed, the survey was conducted online via the Internet: https://forms.gle/WjCSnNHbZ csdMoRy9.
86 students of KSMU took part in the survey. Among the respondents, 79.1% of respondents are girls, 20.9% are boys under the age of 18 (2.3%), 18-20 years (51.2%) and 21-25 years (46.5%). 46.5% of respondents are students of the Faculty of Medicine, 30.2% are students of the Faculty of Pharmacy, 7% are students of the Faculty of Medicine and Prevention, 4.7% are students of the Faculty of Biotechnology, faculties of Clinical Psychology and Social Work, 2.3% are students of the Faculty of Dentistry. 41.9% of respondents are 4th–year students, 30.2% are 3rd–year students, 16.3% are 2nd–year students, 9.3% are first–year students and 2.3% of respondents are residents. The sample was compiled in such a way that absolutely all respondents suffered a new coronavirus infection at least once during the pandemic.
It is noteworthy that 60.5% of students came to the conclusion that they had suffered a new coronavirus infection on their own, based on symptoms and epidemiological history. Only 39.5% of respondents during the disease had a confirmed positive result of PCR testing for the detection of SARS-CoV-2 RNA. After undergoing the disease, only 18.6% of students have a high titer of antibodies to coronavirus, 16.3% of respondents have a low titer of antibodies, and 65.1% of respondents took a blood test to detect the level of immunoglobulins. 79.1% of the students studied were vaccinated.
55.8% of respondents were treated independently at home, without medical assistance, 39.5% of students were treated on an outpatient basis, with a visit to a visiting medical team, and 4.7% were hospitalized and received treatment in a hospital. 74.4% of students had less than 14 days from the moment of illness to full recovery, 25.6% of respondents had the disease from 14 days to 21 days. Fever (an increase in body temperature above 37 ° C) in 41.9% of students lasted up to 3 days, in 14% – up to 7 days, in 4.7% – more than 7 days, in 23.3% of students hyperthermia lasted for 1 day, and in 23.3% of respondents there was no fever at all.
In the study of pharmacological therapy, which KSMU students used in the treatment of a new coronavirus infection, it was found that among antiviral drugs, umifenovir (arbidol) was most often used – 27.9%, meglumine acridon acetate (cycloferon) was also used as the main etiotropic therapy – 14%, Antibodies to gamma interferon, CD4 and histamine affinally purified (ergoferon) – 11.6%, pentanedioic acid imidazolylethanamide (ingavirin) – 9.3%, gossypol copolymer (kagocel) – 7%, Favipiravir (apifavir) – 4.7%, Enisamia iodide (nobazit) – 4.7%, Oseltamivir – 2.3%, trekrezan – 2.3%. It is noteworthy that 39.5% did not resort to antiviral therapy during their treatment for a new coronavirus infection.
Vitamin C (60.5%), vitamin D (44.2%), vitamin B (20.9%), vitamin A (16.3%) were used as vitamin therapy, which is given a lot of attention in the temporary clinical recommendations for the treatment of NCVI [2]. Glucocorticosteroids (corticosteroids) are drugs used for a new coronavirus infection of moderate severity, in moderate and severe cases of NCVI [2], therefore, most students did not resort to corticosteroids during their therapy, however, 4.7% of respondents received dexamethasone intramuscularly, dexamethasone with intravenous administration (2.3%), dexamethasone drops (2.3%), budesonide inhalation (pulmicort) – 2.3% and fluticasone furoate (2.3%).
Conclusion. According to the results of the study of this sample, it can be said that special attention deserves the fact that most cases of transmission of a new coronavirus infection in the studied population are not confirmed by PCR testing for the detection of SARS-CoV-2 RNA, which may affect the incidence statistics, as well as the treatment protocol in each individual clinical case. The highest frequency of use in the treatment of NKVI was observed in such drugs as umifenovir (27.9%), gripferon in the form of nasal drops (27.9%), vitamin C (60.5%), vitamin D (44.2%), and vitamin B (20.9%). The therapy of a new coronavirus infection used by students corresponds to the schemes described in the temporary clinical recommendations for the treatment of NCVI [2], and is also effective.

×

About the authors

Mariia Dubinina

Kursk state medical university

Email: dubinoria@yandex.ru
ORCID iD: 0000-0003-3328-8533
Russian Federation, 305001, Kursk, K.Marks street 3

Natalia V. Boldina

Курский государственный медицинский университет

Author for correspondence.
Email: kursk.252@yandex.ru
ORCID iD: 0000-0003-4068-4083
Russian Federation, 3050001, г Курск, ул. Карла Маркса, 3

References

  1. Воробьёв, П.А. Постковидный синдром. [Электронный ресурс] // Лекция профессора Воробьёва П. А. – 2021. URL: https://youtu.be/FB4EGWgb4VQ (дата обращения 17.02.2022).
  2. Временные методические рекомендации профилактика, диагностика и лечение новой коронавирусной инфекции (covid-19), версия 14 (27.12.2021).
  3. Заплатников, А.Л. COVID-19 и молодое поколение / Заплатников, А.Л. Свинцицкая В.И.//. – РМЖ. –2020. – №1. С. 1–3.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies